Results 41 to 50 of about 24,516 (282)

Guillain-Barré syndrome: a century of progress [PDF]

, 2016
In 1916, Guillain, Barré and Strohl reported on two cases of acute flaccid paralysis with high cerebrospinal fluid protein levels and normal cell counts — novel findings that identified the disease we now know as Guillain–Barré syndrome (GBS).
A Campbell, A Chiba, A Chiba, A Pestronk, A Uncini, AA Ilyas, AD Langmuir, AJ Sumner, AK Asbury, AK Asbury, AK Asbury, AM Fitzpatrick, B Parra, B van den Berg, BH Waksman, C Brechenmacher, C Fokke, C Hafer-Macko, C Linington, CE Hafer-Macko, CL Schengrund, CP O'Leary, E Díez-Tejedor, FG van der Meché, FH Geisler, G Guillain, GM McKhann, GM O'Hanlon, H Wis´niewski, HJ Willison, Hugh J. Willison, J Kaldor, J Matias-Guiu, JA Goodfellow, JC Dodge, JG McLeod, JH Rees, JJ Plomp, JM Pearce, John A. Goodfellow, JW Albers, JW Griffin, JW Prineas, K Kaida, K Susuki, KE Astrom, KM Rhodes, KN Greenshields, LB Schonberger, LD Osler, LM Araujo, LT Kurland, M Fisher, M Kadlubowski, M Vermeulen, MK White, N Shahrizaila, N Yuki, N Yuki, N Yuki, N Yuki, NA Gregson, O Landry, PA van Doorn, PO Osterman, R McGonigal, R McGonigal, R van Koningsveld, RA Hughes, RA Hughes, RJ Greenwood, RP Kleyweg, S Draganescu, S Kusunoki, S Lafontaine, S Rinaldi, S Rinaldi, S Rinaldi, SK Halstead, SK Halstead, SK Halstead, T Lasky, T Saida, TE Feasby, TE Feasby, TW Ho, TW Ho, VM Cao-Lormeau, W Wiederholt, W Yan, WE Haymaker, Y Nagai   +91 more
core   +1 more source

Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study

Internal medicine, 2023
Objective Molecular-targeted agents, including eculizumab and rituximab, are considered treatment options for refractory myasthenia gravis (MG), but bacterial infections can occur as serious adverse events when using these agents.
Shohei Okusa, T. Takizawa, Shungo Imai, M. Oyama, Kei Ishizuchi, Jin Nakahara, Satoko Hori, Shigeaki Suzuki   +7 more
semanticscholar   +1 more source

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

Haematologica, 2010
Background Paroxysmal nocturnal hemoglobinuria is an acquired hemolytic anemia characterized by intravascular hemolysis which has been demonstrated to be effectively controlled with eculizumab.
Anita Hill, Russell P. Rother, Louise Arnold, Richard Kelly, Matthew J. Cullen, Stephen J. Richards, Peter Hillmen   +6 more
doaj   +1 more source

Sublytic Terminal Complement Components Induce Eryptosis in Autoimmune Haemolytic Anaemia Related to IgM Autoantibodies [PDF]

, 2019
BACKGROUND/AIMS: Eryptosis, the suicidal death of red blood cells (RBCs), is characterized by phosphatidylserine (PS) exposure at the cell surface. It can be catalysed by a variety of abnormal conditions and diseases.
Balola, Abdelwahab Hassan Ahmed, Bartolmäs, Thilo, Mayer, Beate, Salama, Abdulgabar   +3 more
core   +1 more source

Treating C3 glomerulopathy with eculizumab

BMC Nephrology, 2018
Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well as inherited dysregulation of the alternative pathway of the complement cascade ...
Thomas Welte, Frederic Arnold, Julia Kappes, Maximilian Seidl, Karsten Häffner, Carsten Bergmann, Gerd Walz, Elke Neumann-Haefelin   +7 more
doaj   +1 more source

Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method

BioDrugs, 2023
Background SB12 is being developed as a proposed biosimilar to eculizumab reference product (RP), a humanized monoclonal antibody (IgG2/4 kappa immunoglobulin) that binds to the human C5 complement protein.
Hyunsoo Kim, Eunkyoung Hong, Jungmin Lee, S. Hong, Jihye Kim, Miju Cho, Yikwon Kim, Taek-Soo Yoo   +7 more
semanticscholar   +1 more source

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy

Frontiers in Pediatrics, 2021
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT) associated with high morbidity and mortality. High-risk TA-TMA (hrTA-TMA) is characterized by multifactorial
Laura Gomez-Ganda, Maria Isabel Benitez-Carabante, Aurora Fernandez-Polo, Marina Muñoz-Lopez, Berta Renedo-Miro, Gema Ariceta, Cristina Diaz De Heredia   +6 more
doaj   +1 more source

The long‐acting anti‐C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab

British Journal of Haematology, 2023
The extreme and peculiar susceptibility of paroxysmal nocturnal haemoglobinuria (PNH) red cells to activated complement is the main mechanism of intravascular haemolysis and anaemia in this acquired disease.
M. Sica, F. Barone, Caterina Nannelli, P. Ricci, L. Marano, M. De Angioletti, E. di Bona, A. Risitano, R. Notaro   +8 more
semanticscholar   +1 more source

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes [PDF]

, 2017
C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients, may undergo extravascular hemolysis ...
A Hill, A Hill, A Nicholson-Weller, A Roth, AM Risitano, AM Risitano, AM Risitano, AM Risitano, AM Risitano, Antonio M. Risitano, B Nilsson, CE Schoot van der, DJ Araten, DS Holt, E Lach-Trifilieff, E Marchiafava, G Gronowicz, GL Logue, GV Seaman, J Nishimura, J Takeda, JD Tamerius, JE May, JP Atkinson, JV Dacie, L Luzzatto, L Luzzatto, L Luzzatto, M Bessler, M Harboe, M Kono, M Loschi, M Sica, M Sica, MA Lindorfer, Maria De Angioletti, MH Holguin, Michela Sica, MJ Harder, MK Pangburn, MK Pangburn, P Hillmen, P Hillmen, P Hillmen, Patrizia Ricci, PJ Lachmann, PJ Lachmann, RJ Kelly, RL Sparrow, Rosario Notaro, RP Latour de, RP Rother, S Berentsen, SK Krishnan, T Olutogun, T Rondelli, TH Ham, Tommaso Rondelli, UM Reiss, VM Holers, VP Ferreira, WF Rosse, WF Rosse, Z Fishelson, Z Lin   +64 more
core   +2 more sources

A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients

Journal of Neurology
Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both
Chiara Pane, Vincenzo Di Stefano, N. Cuomo, A. Sarnataro, C. Vinciguerra, L. Bevilacqua, F. Brighina, N. Rini, G. Puorro, A. Marsili, Matteo Garibaldi, L. Fionda, Francesco Saccà   +12 more
semanticscholar   +1 more source